Ultra High-Volume Scanners

WHITE PAPERS AND CASE STUDIES

• Compliance Auditing: Diving Into Common Critical Findings

  Review critical findings in compliance audits, highlighting frequent issues, their impact on operations, and steps companies can take to improve regulatory compliance.

• Optimizing DSP Development: Faster Timelines, Lower Costs, And High-Quality Processes

  The biopharmaceutical industry faces growing downstream processing challenges in purifying complex biologics efficiently and at scale.

• 82 Million Gallons In. Zero PFAS Out.

  Ion exchange resin is a reliable, high-capacity solution for municipal PFAS treatment, demonstrating zero detectable PFAS after processing 82 million gallons of water. The technology offers a significantly smaller footprint and superior volumetric capacity compared to GAC. Read the full case study to review performance data and strategic impacts.

• Exploring Perfusion Technology For Virus Manufacturing Process Intensification

  Perfusion cell culture technology supports high cell densities and product yields for viral vaccine manufacturing, offering a reliable way to produce high-quality cells at a commercial scale.

• Bridging The Gap During Organizational Restructuring For Continuity

  Navigating workforce turnover and restructuring can threaten project timelines. Discover how leveraging an experienced on-site team can ensure long-term continuity.

• A Strategic Guide For Biotech And Biopharma Leaders

  Securing drug approval is a complex, high-stakes process, and outdated review workflows hinder progress. Explore modern solutions that accelerate timelines without compromising compliance or quality.

• Overcoming HCP Co-Elution Issues Using Cell Line Engineering

  Product quality assessments revealed that a customer’s therapeutic protein had a range of hydrophobic HCPs. Review a solution that took an alternative approach by utilizing cell line engineering.

• A Paperless Lab Simplifies, Accelerates Full Sample Lifecycle Data Management

  Implementing IDBS’ ELN helped Crown Bioscience realize electronic experimental records, optimizing our business processes and helping them to be more standardized.

• Writing An IND Module 3 For Cell And Gene Therapy Products

  This whitepaper outlines the critical considerations for CGT Investigational New Drug (IND) Module 3, as well as how to avoid clinical holds and ensure regulatory readiness.

• The True ROI Of Decentralized Clinical Trials

  Gain a greater understanding of how the right DCT solution, or combination of solutions, coupled with clear metrics and expert guidance on execution, can demonstrate tangible, quantitative ROI in clinical trials.

• Elevating mRNA Manufacturing Toward GMP-Readiness

  The mRNA Technology Transfer Program empowers LMICs with scalable vaccine production. Learn about a partnership that drives innovation in mRNA and sets a global blueprint for equitable health access.

• UV Treatment Upgrades In Wales

  In order to improve the treatment performance (because of the continued cost to maintain compliance), and ensure that it would eventually have the treatment capacity to meet future population growth equivalent of up to 225,000, Swansea WwTW was in need of an equipment upgrade.